Camargo

Samer E. Kaba, M.D. has been named vice president of clinical development and chief medical officer, Camargo. Dr. Kaba will be responsible for the company’s research services and clinical development.

Dr. Kaba joins the company with more than 20 years of combined clinical practice and clinical research, experience in academia, private practice and the pharmaceutical industry. He is a board certified neurologist with additional fellowship training in neuro-immunology and neuro-oncology. Dr. Kaba has experience in protocol development and conducting clinical trials in a variety of therapeutic indications in Phases I-IV.

“The addition of a chief medical officer signals our strong dedication to having a team with enormous depth and breadth. We are quite excited to have Dr. Kaba join Camargo, his ability to apply medical expertise in a clinical research setting will provide our clients with additional support in developing their strategic programs,” stated president and chief executive officer, Ken Phelps. “Our expertise in 505(b)(2) drug development extends to the specialized designs of the clinical program. Dr. Kaba will enhance our ability to deliver efficient clinical trials to our clients.”

Dr. Kaba most recently served as vice president of global medical affairs and strategic product development at Premier Research Group. He managed a team of physicians across the globe and served on the company’s senior executive committee. Dr. Kaba also provided input on the strategic and tactical aspects of clinical trials (study design, selection of countries, selection of investigative sites, designing and conducting feasibility studies, etc.) and facilitated communication with key opinion leaders and principal investigators.